PepGen Inc. (PEPG)
NASDAQ: PEPG · IEX Real-Time Price · USD
16.57
+0.02 (0.09%)
Jul 22, 2024, 12:02 PM EDT - Market open
PepGen Employees
PepGen had 64 employees as of December 31, 2023. The number of employees increased by 19 or 42.22% compared to the previous year.
Employees
64
Change (1Y)
19
Growth (1Y)
42.22%
Revenue / Employee
n/a
Profits / Employee
-$1,255,109
Market Cap
532.62M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 64 | 19 | 42.22% |
Dec 31, 2022 | 45 | 14 | 45.16% |
Dec 31, 2021 | 31 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Community Health Systems | 61,000 |
Cross Country Healthcare | 13,131 |
Canopy Growth | 1,029 |
Valneva SE | 676 |
OmniAb | 106 |
PureTech Health | 90 |
Mereo BioPharma Group | 33 |
Contineum Therapeutics | 31 |
PEPG News
- 20 days ago - PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications - Business Wire
- 5 weeks ago - PepGen Announces Executive Team Promotions - Business Wire
- 2 months ago - PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 4 months ago - PepGen to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 4 months ago - PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments - GlobeNewsWire
- 5 months ago - PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 5 months ago - PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 - GlobeNewsWire